Pharmafile Logo
Pharmafocus logo
Advanced Search

Bayer

Showing 15 posts of 262 posts found.

Evotec and Bayer announce new kidney disease study

December 11, 2025
Research and Development Bayer, Evotec, Nephrology

Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney disease, stemming from their previous …

News

Third application for Orion’s prostate cancer drug submitted by partner Bayer

September 23, 2024
Bayer, Cancer, Oncology, orion, prostate cancer

Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …

News

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024
Research and Development Bayer, Cardiology, cardio, cvd

Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of …

News

Bayer and Aignostics to collaborate for AI oncology research

March 14, 2024
Research and Development AI, Bayer, Oncology, research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several artificial intelligence (AI)-powered approaches for …

News

Bayer’s cardiovascular drug shows impressive Phase III results

May 11, 2021
Manufacturing and Production Bayer, chronic kidney disease, pharma, pharma news, type 2 diabetes

Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events in patients with chronic kidney …

News
xarelto_10_tablet1

Bayer’s venous thromboembolism drug Xarelto gets UK approval for children

February 1, 2021
Sales and Marketing Bayer

Bayer has received UK approval for the use of its oral Factor Xa inhibitor Xarelto (rivaroxaban) to treat venous thromboembolism …

News

Bayer and CureVac to collaborate on COVID-19 vaccine candidate

January 8, 2021
Medical Communications Bayer, COVID-19, Vaccine

Bayer is joining forces with CureVac, a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA), on its COVID-19 …

News

Bayer buys out US-based Asklepios BioPharmaceutical in potential $4bn deal

October 26, 2020
Sales and Marketing Asklepios, Bayer, acquisition, pharma

Bayer has moved to bolster its cell and gene therapy (CGT) business through the acquisition of US biotech Asklepios BioPharmaceutical …

News
nice_new_london_office_internal_3_web

Bayer’s Nubeqa secures NICE recommendation for hormone-relapsed prostate cancer at risk of metastasis

October 23, 2020
Medical Communications, Sales and Marketing Bayer, NCIE, Nubeqa, pharma

NICE has given its recommendation to Bayer’s androgen receptor inhibitor Nubeqa (darolutamide) in combination with androgen deprivation therapy (ADT) for …

News
shutterstock_273326141

Bayer scoops up women’s healthcare biotech KaNDy Therapeutics in potential $1bn+ deal

August 11, 2020
Manufacturing and Production, Research and Development, Sales and Marketing Bayer, KaNDy Therapeutics, menopause, pharma

Bayer is set to acquire UK-based biotech KaNDy Therapeutics, assimilating the firm’s women’s healthcare development portfolio in a newly announced …

News
fda

FDA grants fast review for Bayer and MSD’s heart failure drug vericiguat

July 17, 2020
Medical Communications Bayer, FDA, MSD

The FDA has granted a fast Priority Review for Bayer and MSD’s heart failure drug vericiguat. This was based on …

News

Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer

April 21, 2020
Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …

News

Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

March 31, 2020
Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …

News
gwpharma

GW Pharma takes back control of UK Sativex sales from Bayer

March 2, 2020
Sales and Marketing Bayer, GW Pharma, Sativex, UK

British firm GW Pharmaceuticals has revealed that it plans to reclaim the commercialisation rights to market its cannabis-based multiple sclerosis …

News

Bayer’s Eylea shows strong vision benefits across two regimens in post-marketing study

February 5, 2020
Research and Development Bayer, Eylea, pharma

Bayer has pulled back the curtain on new Phase 4 data for Eylea (aflibercept), revealing strong findings in the treatment …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025